GEN Exclusives

More »

GEN News Highlights

Back to Item »

Agennix Stops Phase II/III Talactoferrin Study in Sepsis Due to Higher Death Rates

Move doesn't affect ongoing Phase III studies evaluating recombinant lactoferrin against NSCLC.

Forward this item to a colleague:


(Separate multiple addresses by commas)


(Separate multiple addresses by commas)


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »